FGF15/19-mediated activation of SHP via phosphorylation is important for its nuclear localization21,38 and FGF15/19 signaling was shown to be impaired in NAFLD patients and obese mice21,42,43, which is consistent with reduced phosphorylation of SHP and consequently, decreased nuclear levels of SHP in the patients and obese mice. The gene discussed is NR0B2; the disease is metabolic dysfunction-associated steatotic liver disease.